BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37643508)

  • 1. Management of humoral secondary immunodeficiency in hematological malignancies and following hematopoietic stem cell transplantation: Regional perspectives.
    Ar MC; El Fakih R; Gabbassova S; Alhuraiji A; Nasr F; Alsaeed A; Sayinalp N; Marashi M
    Leuk Res; 2023 Oct; 133():107365. PubMed ID: 37643508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.
    Na IK; Buckland M; Agostini C; Edgar JDM; Friman V; Michallet M; Sánchez-Ramón S; Scheibenbogen C; Quinti I
    Eur J Haematol; 2019 Jun; 102(6):447-456. PubMed ID: 30801785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Approach in the Management of Secondary Immunodeficiency in Patients with Hematological Malignancies: Spanish Expert Consensus Recommendations.
    Boqué C; Sánchez-Ramón S; Córdoba R; Moreno C; Cabezudo E
    J Clin Med; 2023 Oct; 12(19):. PubMed ID: 37835000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia.
    Ohmoto A; Fuji S; Shultes KC; Savani BN; Einsele H
    Bone Marrow Transplant; 2022 Jun; 57(6):874-880. PubMed ID: 35440805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants.
    Monleón Bonet C; Waser N; Cheng K; Tzivelekis S; Edgar JDM; Sánchez-Ramón S
    Expert Rev Clin Immunol; 2020 Sep; 16(9):911-921. PubMed ID: 32783541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency.
    Benbrahim O; Viallard JF; Choquet S; Royer B; Bauduer F; Decaux O; Crave JC; Fardini Y; Clerson P; Lévy V
    Eur J Haematol; 2018 Jul; 101(1):48-56. PubMed ID: 29644723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule.
    Sim B; Ng JY; Teh BW; Talaulikar D
    Leuk Lymphoma; 2023 Jan; 64(1):18-29. PubMed ID: 36218218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management.
    Patel SY; Carbone J; Jolles S
    Front Immunol; 2019; 10():33. PubMed ID: 30800120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Access and use of immunoglobulins in supportive cancer care: A thematic analysis of a systematic review data set.
    Counihan M; Cervenakova L; Misztela D; Van Baelen M; D Naughton B
    J Med Access; 2024; 8():27550834241236596. PubMed ID: 38559466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinician survey for management of the secondary immunodeficiency caused by hematological malignancies in China.
    Ye C; Liu J; Song X; Zheng S; Liu J
    Medicine (Baltimore); 2021 Jan; 100(3):e23935. PubMed ID: 33545966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: a representative analysis of guideline adherence and infections.
    Link H; Kerkmann M; Holtmann L; ;
    Support Care Cancer; 2022 Jun; 30(6):5187-5200. PubMed ID: 35257229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced risk of infections with the intravenous immunoglobulin, IgPro10, in patients at risk of secondary immunodeficiency-related infections.
    Lahue BJ; Mallick R; Zhang X; Heidt J; Song Y; Koenig AS; Espinoza G
    Immunotherapy; 2022 Oct; 14(15):1245-1261. PubMed ID: 35971794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary Immune Deficiency and Primary Immune Deficiency Crossovers: Hematological Malignancies and Autoimmune Diseases.
    Ballow M; Sánchez-Ramón S; Walter JE
    Front Immunol; 2022; 13():928062. PubMed ID: 35924244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review.
    Jolles S; Giralt S; Kerre T; Lazarus HM; Mustafa SS; Ria R; Vinh DC
    Front Oncol; 2023; 13():1098326. PubMed ID: 36824125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency.
    Patel V; Cowan J
    Expert Rev Clin Immunol; 2020 Jul; 16(7):711-716. PubMed ID: 32588670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies.
    Heftdal LD; Hamm SR; Pérez-Alós L; Madsen JR; Armenteros JJA; Fogh K; Kronborg CC; Vallentin AP; Hasselbalch RB; Møller DL; Hansen CB; Pries-Heje M; Gang AO; Ostrowski SR; Frikke-Schmidt R; Sørensen E; Hilsted L; Bundgaard H; Iversen K; Garred P; Nielsen SD; Grønbaek K
    Eur J Haematol; 2023 Aug; 111(2):229-239. PubMed ID: 37151174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infections in secondary immunodeficiency patients treated with Privigen
    Mallick R; Divino V; Smith BD; Jolles S; DeKoven M; Vinh DC
    Leuk Lymphoma; 2021 Dec; 62(14):3463-3473. PubMed ID: 34569910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia.
    Compagno N; Malipiero G; Cinetto F; Agostini C
    Front Immunol; 2014; 5():626. PubMed ID: 25538710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of hypogammaglobulinemia and its management with subcutaneous immunoglobulin supplementation in patients after allogeneic hematopoietic stem cell transplantation-a single-center analysis.
    Karakulska-Prystupiuk E; Dwilewicz-Trojaczek J; Drozd-Sokołowska J; Kmin E; Chlebus M; Szczypińska K; Boguradzki P; Tomaszewska A; Mądry K; Biliński J; Basak GW; Jędrzejczak WW
    Ann Hematol; 2021 Dec; 100(12):3007-3016. PubMed ID: 34477951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments.
    Benbrahim O; Viallard JF; Choquet S; Royer B; Bauduer F; Decaux O; Crave JC; Fardini Y; Clerson P; Lévy V
    Hematology; 2019 Dec; 24(1):173-182. PubMed ID: 30458690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.